AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33778854 — intervention group
Group type: COMPARATOR
Intervention: Sales ban only (for individuals with stronger cravings)
Number of subjects: 214
Study 32791030 — intervention group
Group type: EXPERIMENTAL
Intervention: Castration with docetaxel
Number of subjects: 0
Study 32791030 — intervention group
Group type: COMPARATOR
Intervention: Castration without docetaxel
Number of subjects: 0
Study 34724670 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 seconds freezing time
Number of subjects: 100
Study 34724670 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 seconds freezing time
Number of subjects: 100
Study 34724670 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 seconds freezing time
Number of subjects: 100
Study 34724670 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 seconds freezing time
Number of subjects: 100
Study 33331448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted (FASTED, n=13)
Number of subjects: 25
Study 33331448 — intervention group
Group type: COMPARATOR
Intervention: Fed (FED, n=12)
Number of subjects: 25
Study 35476115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg child weight)
Number of subjects: 0
Study 35476115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32710862 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement package for intrapartum and immediate newborn care, including provider mentoring using PRONTO simulation and team training, and quality improvement collaboratives.
Number of subjects: 2938
Study 32710862 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving maternity register data strengthening and a modified WHO Safe Childbirth Checklist.
Number of subjects: 2938
Study 36085409 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-marginal instrumentation before surgical treatment
Number of subjects: 42
Study 36085409 — intervention group
Group type: COMPARATOR
Intervention: Supra-marginal instrumentation only
Number of subjects: 42
Study 34246761 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-treatment group (8 weeks of binocular treatment using therapeutic software application in virtual reality headset)
Number of subjects: 20
Study 34246761 — intervention group
Group type: COMPARATOR
Intervention: Sham-crossover group (4 weeks of sham treatment followed by 4 weeks of binocular treatment)
Number of subjects: 20
Study 34246761 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-treatment group
Number of subjects: 20
Study 34246761 — intervention group
Group type: COMPARATOR
Intervention: Sham-crossover group
Number of subjects: 20
Study 35956935 — intervention group
Group type: COMPARATOR
Intervention: NanoBEO (essential oil of bergamot) administered as a single therapeutic dose via an airless dispenser.
Number of subjects: 0
Study 33823257 — intervention group
Group type: EXPERIMENTAL
Intervention: CYDAR image fusion guidance
Number of subjects: 37
Study 33823257 — intervention group
Group type: COMPARATOR
Intervention: Standard 2D fluoroscopy
Number of subjects: 37
Study 32171512 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum (COL)
Number of subjects: 24
Study 32171512 — intervention group
Group type: COMPARATOR
Intervention: Whole Milk (WM)
Number of subjects: 24
Study 32171512 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 Colostrum:Milk Mixture (MIX)
Number of subjects: 24
Study 36118977 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS)
Number of subjects: 0
Study 36118977 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34785535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate therapy
Number of subjects: 4996
Study 34785535 — intervention group
Group type: COMPARATOR
Intervention: No fenofibrate therapy
Number of subjects: 4996
Study 33399379 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with concrete words
Number of subjects: 75
Study 33399379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with abstract words
Number of subjects: 75
Study 33399379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no words)
Number of subjects: 75
Study 32404062 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics administered twice daily during antibiotic treatment for up to 1 week after completion of antibiotics
Number of subjects: 93
Study 32404062 — intervention group
Group type: COMPARATOR
Intervention: No probiotics supplementation
Number of subjects: 93
Study 35694717 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed regimen (individualized volume of polyethylene glycol based on stool consistency or water content)
Number of subjects: 531
Study 35694717 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed regimen
Number of subjects: 531
Study 35694717 — intervention group
Group type: COMPARATOR
Intervention: Fixed-volume group (standard volume of polyethylene glycol)
Number of subjects: 531
Study 35694717 — intervention group
Group type: COMPARATOR
Intervention: Fixed-volume group
Number of subjects: 531
Study 35121932 — intervention group
Group type: EXPERIMENTAL
Intervention: Flt3 ligand (CDX-301) pre-treatment with anti-DEC-205-NY-ESO-1 vaccine
Number of subjects: 0
Study 35121932 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-DEC-205-NY-ESO-1 vaccine without Flt3 ligand)
Number of subjects: 0
Study 36171631 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted distal gastrectomy (RADG)
Number of subjects: 1164
Study 36171631 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic-assisted distal gastrectomy (LADG)
Number of subjects: 1164
Study 34032900 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (> 2.1 g protein/kg lean body mass/day)
Number of subjects: 11
Study 34032900 — intervention group
Group type: COMPARATOR
Intervention: Recommended protein intake (1.1 g protein/kg lean body mass/day)
Number of subjects: 11
Study 32416309 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Therapy (SET) - three times weekly supervised treadmill exercise
Number of subjects: 309
Study 32416309 — intervention group
Group type: COMPARATOR
Intervention: Control - lectures on health-related topics
Number of subjects: 309
Study 32416309 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Therapy (SET) - participants attending at least 70% of sessions
Number of subjects: 309
Study 32416309 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Therapy (SET) - participants with baseline six-minute walk distance less than median (334 meters)
Number of subjects: 309
Study 34067261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt‐chrome‐based metal‐ceramic prostheses (MC)
Number of subjects: 129
Study 34067261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt‐chrome‐based metal‐ceramic prostheses using CAD/CAM (CC‐MC)
Number of subjects: 129
Study 34067261 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia‐based ceramic prostheses using CAD/CAM (CC‐Zr)
Number of subjects: 129
Study 34067261 — intervention group
Group type: COMPARATOR
Intervention: Control group (MC, CC‐MC, CC‐Zr)
Number of subjects: 129
Study 35723596 — intervention group
Group type: EXPERIMENTAL
Intervention: SSGL (3v3 in large fixed area)
Number of subjects: 12
Study 35723596 — intervention group
Group type: COMPARATOR
Intervention: SSGS (3v3 in small fixed area)
Number of subjects: 12
Study 35723596 — intervention group
Group type: EXPERIMENTAL
Intervention: SSGD (3v3 in dynamic dimensions)
Number of subjects: 12
Study 33472390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 72
Study 33472390 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 72
Study 32497736 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus bevacizumab (TT–B)
Number of subjects: 153
Study 32497736 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus bevacizumab (C–B)
Number of subjects: 153
Study 616626291 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 60
Study 616626291 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (control group)
Number of subjects: 60
Study 35316121 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) program
Number of subjects: 87
Study 35316121 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) program (subgroup with severe mental illness)
Number of subjects: 87
Study 35316121 — intervention group
Group type: COMPARATOR
Intervention: treatment-as-usual (TAU) group
Number of subjects: 87
Study 32529966 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychedelic-assisted therapy (psilocybin, LSD, ayahuasca, MDMA)
Number of subjects: 9
Study 32529966 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 9
Study 35092084 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐VAR (manipulation of load, volume, muscle action, and rest interval at each RT session)
Number of subjects: 20
Study 35092084 — intervention group
Group type: COMPARATOR
Intervention: RT‐CON (without specific variables manipulations)
Number of subjects: 20
Study 33223453 — intervention group
Group type: EXPERIMENTAL
Intervention: ICGFC-LC
Number of subjects: 63
Study 33223453 — intervention group
Group type: COMPARATOR
Intervention: Conventional LC
Number of subjects: 63
Study 33223453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 32940866 — intervention group
Group type: EXPERIMENTAL
Intervention: LADS
Number of subjects: 20
Study 32940866 — intervention group
Group type: COMPARATOR
Intervention: BPD/DS
Number of subjects: 20
Study 36070760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain competence training with depression prevention (Debora)
Number of subjects: 422
Study 36070760 — intervention group
Group type: COMPARATOR
Intervention: Pain competence training without depression prevention (Control Group)
Number of subjects: 422
Study 36070760 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (Debora)
Number of subjects: 422
Study 36070760 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high levels of depressive symptoms
Number of subjects: 422
Study 36070760 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low depressive symptoms
Number of subjects: 422
Study 36100930 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBOT) - 90 min at 203 kPa daily for 20 days
Number of subjects: 59
Study 32394723 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate (DMPA‐IM)
Number of subjects: 382
Study 32394723 — intervention group
Group type: COMPARATOR
Intervention: Copper Intrauterine Device (IUD)
Number of subjects: 382
Study 35731065 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training sessions on a cycle ergometer (50‐60% heart rate reserve, moderate intensity)
Number of subjects: 40
Study 35731065 — intervention group
Group type: COMPARATOR
Intervention: Selected physical therapy program only (Control group)
Number of subjects: 40
Study 34480773 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-session online imaginal exposure therapy (n=65)
Number of subjects: 130
Study 34480773 — intervention group
Group type: COMPARATOR
Intervention: Control online writing and thinking intervention (n=65)
Number of subjects: 130
Study 34480773 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure therapy
Number of subjects: 130
Study 34480773 — intervention group
Group type: COMPARATOR
Intervention: Control online writing and thinking intervention
Number of subjects: 130
Study 32755496 — intervention group
Group type: EXPERIMENTAL
Intervention: Wired portable amplifier (Device A)
Number of subjects: 22
Study 32755496 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless stationary amplifier (Device B)
Number of subjects: 22
Study 32755496 — intervention group
Group type: EXPERIMENTAL
Intervention: One-way personal communication system (Device C)
Number of subjects: 22
Study 32755496 — intervention group
Group type: COMPARATOR
Intervention: No device
Number of subjects: 22
Study 616119991 — intervention group
Group type: EXPERIMENTAL
Intervention: ETDRS PRP plus IVR (SS-PRP group)
Number of subjects: 44
Study 616119991 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL PRP plus IVR (MS-PRP group)
Number of subjects: 44
Study 616119991 — intervention group
Group type: EXPERIMENTAL
Intervention: Only IVR (IVR group)
Number of subjects: 44
Study 34935979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and neck-specific exercises
Number of subjects: 69
Study 32295624 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg of body mass)
Number of subjects: 22
Study 32295624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34570916 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.4 mg once-daily subcutaneous
Number of subjects: 67
Study 34570916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 32862194 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 2
Study 32862194 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 2
Study 34254983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's own milk
Number of subjects: 114
Study 34254983 — intervention group
Group type: COMPARATOR
Intervention: Donor milk
Number of subjects: 114
Study 34254983 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal ethnicity
Number of subjects: 114
Study 34254983 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal prepregnancy BMI
Number of subjects: 114
Study 34254983 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI ≥30
Number of subjects: 114
Study 34254983 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age and income
Number of subjects: 114
Study 35212023 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral estradiol
Number of subjects: 40
Study 35212023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 40
Study 35212023 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol treatment
Number of subjects: 40
Study 35212023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive complaints (self-reported)
Number of subjects: 40
Study 33765420 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily
Number of subjects: 194
Study 33765420 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (phenprocoumon, acenocoumarol, or warfarin; target INR 2.0-3.0) for 90 days
Number of subjects: 194
Study 33765420 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist
Number of subjects: 194
Study 35524896 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing icon arrays illustrating side effect risk
Number of subjects: 2046
Study 35524896 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2046
Study 32017992 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management at ≥37 weeks of gestation
Number of subjects: 5498
Study 32017992 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous labor
Number of subjects: 5498
Study 32017992 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced labor
Number of subjects: 5498
Study 35394123 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-mg azithromycin test formulation
Number of subjects: 77
Study 35394123 — intervention group
Group type: COMPARATOR
Intervention: 250-mg azithromycin reference formulation
Number of subjects: 77
Study 34819147 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose calcium supplementation (500 mg elemental calcium/day)
Number of subjects: 22000
Study 34819147 — intervention group
Group type: COMPARATOR
Intervention: Standard high-dose calcium supplementation (1500 mg elemental calcium/day)
Number of subjects: 22000
Study 35819099 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group (n=29)
Number of subjects: 58
Study 35819099 — intervention group
Group type: COMPARATOR
Intervention: Telephone group (n=29)
Number of subjects: 58
Study 34294051 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal behavioral lifestyle intervention (PBLI) delivered via group based phone counseling (GBPC)
Number of subjects: 41
Study 34294051 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 41
Study 35787963 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning models (random forest, support vector machine [SVM], logistic regression)
Number of subjects: 423
Study 35787963 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid Randomization After Significant Head Injury (CRASH) model
Number of subjects: 423
Study 35787963 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning models (random forest, SVM, logistic regression)
Number of subjects: 423
Study 32944940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cabbage leaves
Number of subjects: 2170
Study 32944940 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature cabbage leaves
Number of subjects: 2170
Study 32944940 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal compress
Number of subjects: 2170
Study 32944940 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy plus cactus and aloe compress
Number of subjects: 2170
Study 32944940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cactus and aloe cold compress
Number of subjects: 2170
Study 32944940 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage plus cactus and aloe cold compress
Number of subjects: 2170
Study 32944940 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease
Number of subjects: 2170
Study 32944940 — intervention group
Group type: EXPERIMENTAL
Intervention: Serrapeptase
Number of subjects: 2170
Study 32944940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold gel packs
Number of subjects: 2170
Study 33851682 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional stainless steel crown restoration
Number of subjects: 25
Study 33851682 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall technique
Number of subjects: 25
Study 33851682 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 25
Study 35905867 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital users (n=368)
Number of subjects: 2431
Study 35905867 — intervention group
Group type: COMPARATOR
Intervention: Matched nonusers (n=368)
Number of subjects: 2431
Study 33709626 — intervention group
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r 30-20/100-100 (30 mg once weekly with ritonavir 100 mg in the morning, and 20 mg with ritonavir 100 mg in the evening)
Number of subjects: 20
Study 33709626 — intervention group
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r 30-20/200-200
Number of subjects: 20
Study 33709626 — intervention group
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r 30-20/200-100
Number of subjects: 20
Study 33709626 — intervention group
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r 20-20/200-100
Number of subjects: 20
Study 33709626 — intervention group
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r (various cohorts)
Number of subjects: 20
Study 32212800 — intervention group
Group type: EXPERIMENTAL
Intervention: m-DCF regimen (docetaxel 40 mg/m2, cisplatin 40 mg/m2, 5-fluorouracil 400 mg/m2)
Number of subjects: 40
Study 32212800 — intervention group
Group type: COMPARATOR
Intervention: EOX regimen (epirubicin 50 mg/m2, oxaliplatin 130 mg/m2, capecitabine 625 mg/m2)
Number of subjects: 40
Study 32212800 — intervention group
Group type: COMPARATOR
Intervention: EOX regimen
Number of subjects: 40
Study 32212800 — intervention group
Group type: EXPERIMENTAL
Intervention: m-DCF and EOX regimens
Number of subjects: 40
Study 34294642 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Number of subjects: 0
Study 34294642 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 0
Study 34583675 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP ≤ 22 mg/L combined with rhinorrhea
Number of subjects: 209
Study 34583675 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT ≤ 0.18 ng/mL combined with rhinorrhea
Number of subjects: 209
Study 34583675 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP ≤ 22 mg/L and PCT ≤ 0.18 ng/mL combined with rhinorrhea
Number of subjects: 209
Study 32720546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine lozenge
Number of subjects: 68
Study 32720546 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 68
Study 35288387 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148
Number of subjects: 144
Study 35288387 — intervention group
Group type: COMPARATOR
Intervention: Current intravenous fluid care
Number of subjects: 144
Study 35933415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 150 mg oil twice daily (300 mg daily) for 8 days before chemotherapy
Number of subjects: 54
Study 35933415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) with CAPOX
Number of subjects: 54
Study 35933415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CBD)
Number of subjects: 54
Study 34147245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular block using rocuronium (mean dose 12.7 mg, 0.7 mg kg−1)
Number of subjects: 66
Study 34147245 — intervention group
Group type: COMPARATOR
Intervention: No neuromuscular block
Number of subjects: 66
Study 32346274 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session group intervention
Number of subjects: 62
Study 32346274 — intervention group
Group type: COMPARATOR
Intervention: One-session informational group intervention
Number of subjects: 62
Study 34826148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fexofenadine combined with topical treatment (topical tacrolimus 0.03–0.1% ointment once daily, topical fluticasone propionate 0.05% cream once daily, paraffin‐based emollients) for 8 weeks
Number of subjects: 50
Study 34826148 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment only (topical tacrolimus 0.03–0.1% ointment once daily, topical fluticasone propionate 0.05% cream once daily, paraffin‐based emollients) for 8 weeks
Number of subjects: 50
Study 32051005 — intervention group
Group type: EXPERIMENTAL
Intervention: Mi Puente intervention (includes usual care materials and processes, inpatient visits, and up to 4 weeks of follow-up phone calls)
Number of subjects: 0